Q2 Earnings Estimate for AXSM Issued By Leerink Partnrs

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities research analysts at Leerink Partnrs upped their Q2 2025 earnings per share estimates for Axsome Therapeutics in a report issued on Monday, May 5th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of ($1.21) per share for the quarter, up from their prior estimate of ($1.22). The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics' Q3 2025 earnings at ($1.24) EPS, Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($4.39) EPS, FY2027 earnings at $3.15 EPS, FY2028 earnings at $9.25 EPS and FY2029 earnings at $15.40 EPS.

Other analysts have also recently issued reports about the company. Royal Bank of Canada increased their price objective on Axsome Therapeutics from $190.00 to $193.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 29th. Truist Financial increased their price objective on Axsome Therapeutics from $190.00 to $200.00 and gave the stock a "buy" rating in a research report on Wednesday, February 19th. Needham & Company LLC reaffirmed a "buy" rating and set a $153.00 price objective on shares of Axsome Therapeutics in a report on Tuesday, April 1st. Deutsche Bank Aktiengesellschaft began coverage on Axsome Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $176.00 price objective on the stock. Finally, HC Wainwright dropped their price objective on Axsome Therapeutics from $200.00 to $180.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $172.14.

Axsome Therapeutics Stock Performance

Axsome Therapeutics stock traded down $3.90 during mid-day trading on Thursday, reaching $106.26. 302,302 shares of the company were exchanged, compared to its average volume of 680,762. Axsome Therapeutics has a twelve month low of $64.11 and a twelve month high of $139.13. The firm's 50-day simple moving average is $111.71 and its two-hundred day simple moving average is $104.84. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. The firm has a market cap of $5.23 billion, a PE ratio of -17.74 and a beta of 0.46.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The company had revenue of $118.77 million during the quarter, compared to analysts' expectations of $117.83 million.

Insiders Place Their Bets

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares of the company's stock, valued at $5,529,450.09. This trade represents a 6.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 22.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Several large investors have recently added to or reduced their stakes in AXSM. Assenagon Asset Management S.A. increased its position in Axsome Therapeutics by 16,852.7% in the first quarter. Assenagon Asset Management S.A. now owns 627,418 shares of the company's stock worth $73,176,000 after buying an additional 623,717 shares during the period. Boxer Capital Management LLC acquired a new position in shares of Axsome Therapeutics during the fourth quarter valued at $39,767,000. Lazard Asset Management LLC increased its holdings in shares of Axsome Therapeutics by 525.7% during the fourth quarter. Lazard Asset Management LLC now owns 537,669 shares of the company's stock valued at $45,492,000 after purchasing an additional 451,737 shares during the period. Nuveen LLC acquired a new position in shares of Axsome Therapeutics during the first quarter valued at $48,185,000. Finally, Norges Bank acquired a new position in shares of Axsome Therapeutics during the fourth quarter valued at $34,100,000. 81.49% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.